Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Compagnie Lombard Odier SCmA

Compagnie Lombard Odier SCmA increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 29.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 250,267 shares of the medical research company's stock after buying an additional 56,371 shares during the quarter. Thermo Fisher Scientific accounts for approximately 1.5% of Compagnie Lombard Odier SCmA's holdings, making the stock its 16th biggest holding. Compagnie Lombard Odier SCmA owned about 0.07% of Thermo Fisher Scientific worth $124,533,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in TMO. Semus Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.0% in the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after purchasing an additional 18 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Proactive Wealth Strategies LLC increased its holdings in shares of Thermo Fisher Scientific by 2.7% during the fourth quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company's stock valued at $392,000 after acquiring an additional 20 shares in the last quarter. Cassaday & Co Wealth Management LLC increased its holdings in shares of Thermo Fisher Scientific by 0.9% during the fourth quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company's stock valued at $1,189,000 after acquiring an additional 20 shares in the last quarter. Finally, Callan Capital LLC increased its holdings in shares of Thermo Fisher Scientific by 2.7% during the fourth quarter. Callan Capital LLC now owns 773 shares of the medical research company's stock valued at $402,000 after acquiring an additional 20 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded down $12.78 during trading hours on Friday, hitting $402.12. 1,838,469 shares of the company's stock were exchanged, compared to its average volume of 1,927,137. The firm has a 50 day moving average of $417.11 and a two-hundred day moving average of $493.15. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The firm has a market cap of $151.80 billion, a P/E ratio of 24.33, a P/E/G ratio of 2.99 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the prior year, the company earned $5.11 EPS. The firm's revenue was up .2% compared to the same quarter last year. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.33% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on TMO shares. Citigroup cut their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Evercore ISI dropped their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Royal Bank of Canada dropped their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Robert W. Baird dropped their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Finally, Argus dropped their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $605.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.